Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.76

-2.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zeta1961 who wrote (14239)	11/19/2004 10:11:36 PM
From: Miljenko Zuanic	Read Replies (1) of 52153

Elizabet, more often than not I am wrong than correct. Even when I am correct I am not happy about. I have no opinion on DSCO. Do not follow them. Regards the DNDN, manufacturing problems is in addition to my general concern that they are not up to task that it is in front of them. Maybe, as Rick mentioned, dendrite cells based vaccines have best chances in cancer, but I do not think that DNDN personalized medicine approach is right one. <<Which Iressa data are we waiting for?..>> PIII as br21 trial. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next